Just another WordPress site

Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder

Sep 27, 2022


Objective: Abstinence is rarely achieved in clinical trials for cannabis use disorder (CUD). Cannabis reduction is associated with functional improvement, but reduction endpoints have not been established, indicating a need to identify and validate clinically meaningful reduction endpoints for assessing treatment efficacy. Method: Data from a 12-week double-blind randomized placebo-controlled medication trial for cannabis cessation (NCT01675661) were analyzed. Participants (N = 225) were treatment-seeking adults, M = 30.6 (8.9) years old, 70.2% male, and 42.2% Non-White, with CUD who completed 12 weeks of treatment. Frequency (days of use per week) and quantity (grams per using day) were used to define high-, medium-, and low-risk levels. Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale and cannabis-related problems were assessed using the Marijuana Problems Scale. General linear models for repeated measures tested associations between the magnitude of risk reduction and functional outcomes from baseline (BL) to end-of-treatment (EOT). Results: Cannabis risk levels were sensitive to reductions in use from BL to EOT for frequency- (χ² = 19.35, p = .004) and quantity-based (χ² = 52.06, p < .001) metrics. Magnitude reduction in frequency-based risk level was associated with magnitude decrease in depression (F = 2.76, p = .043, ηp² = .04), anxiety (F = 3.70, p = .013, ηp² = .05), and cannabis-related problems (F = 8.95, p< .001, η p² = .12). Magnitude reduction in quantity-based risk level was associated with magnitude decrease in anxiety (F = 3.02, p = .031, ηp² = .04) and cannabis-related problems (F = 3.24, p = .023, ηp² = .05). Conclusions: Cannabis use risk levels, as operationalized in this study, captured reductions in use during a clinical trial. Risk level reduction was associated with functional improvement suggesting that identifying risk levels and measuring the change in levels over time may be a viable and clinically meaningful endpoint for determining treatment efficacy. (PsycInfo Database Record (c) 2022 APA, all rights reserved)

Impact Statement

Cannabis use risk levels are measurable, and reduction in risk level is associated with functional improvement during treatment. Given increasing access to cannabis worldwide, risk reduction approaches may be critical to reduce the public health burden of cannabis use disorder (CUD). (PsycInfo Database Record (c) 2022 APA, all rights reserved)



Other Posts

Recommended Approaches to Evaluate Methodologies and Technologies for the Detection of Cannabis-Impaired Driving

In September 2023, New York State Department of Health (DOH) issued a Request for Information (RFI) regarding methodologies and technologies used for the detection and assessment of driving under-the-influence of cannabis (DUIC). The RFI purpose is to assist the DOH in assessing the current state of research on impairment due to cannabis ingestion, and to review current devices that can be used to detect impairment. Moreover, the DOH is seeking to identify research institutions in higher education that are currently performing this type of research.

read more

Maryland Medical Cannabis Patient Survey Report 2022

The Maryland Medical Cannabis Commission sponsored this survey and report from Cannabis Public Policy Consulting (CPPC) to examine patterns of use, perceptions of risk and benefit, and occurrence of high-risk
behaviors related to cannabis use in the medical cannabis patient population. More than 13,000 medical cannabis patients took part in the survey, which was conducted in September 2022, prior to the General Election referendum to legalize adult use in the state. A second, post referendum survey is planned for fall 2023.

read more